| paricalcitol / Generic mfg. |
NCT00064376: Paricalcitol in Treating Patients With Myelodysplastic Syndrome |
|
|
| Completed | 2 | | US | paricalcitol | Cedars-Sinai Medical Center, Abbott | Leukemia, Myelodysplastic Syndromes | 11/05 | 11/05 | | |
NCT00053378: A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects |
|
|
| Completed | 2 | 45 | US | paricalcitol injection (Zemplar), Effects on calcium regulation, Administration of elemental Ca during hypocalcemic ICU pts. | Abbott | Hypocalcemia | | | | |
| Completed | 2 | 25 | Japan | paricalcitol, ABT-358, Zemplar | Abbott | Chronic Kidney Disease | 02/07 | | | |
NCT00686751: Immune Effects of Vitamin D in Hemodialysis Patients |
|
|
| Completed | 2 | 20 | US | paricalcitol | Renal Research Institute, Abbott | End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease | 09/07 | 09/07 | | |
NCT00667576: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis |
|
|
| Completed | 2 | 153 | Japan | Maxacalcitol, Paricalcitol, ABT-358, Zemplar | Abbott, Abbott Japan Co.,Ltd | Chronic Kidney Disease on Hemodialysis, Secondary Hyperparathyroidism | 03/09 | 03/09 | | |
VITAL, NCT00421733 / 2006-001363-31: The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors |
|
|
| Completed | 2 | 281 | US, Europe, RoW | Zemplar (paricalcitol ) capsules, ABT-358, paricalcitol, Zemplar, Zemplar (paricalcitol) capsules, Placebo | Abbott | Diabetic Nephropathy, Chronic Kidney Disease | 06/09 | 06/09 | | |
|
NCT00701805: Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) |
|
|
| Completed | 2 | 107 | Japan | Paricalcitol, ABT-358, Zemplar | Abbott, Abbott Japan Co.,Ltd | Secondary Hyperparathyroidism, Hemodialysis | 12/09 | 12/09 | | |
NCT00656032: Vitamin D, Insulin Resistance and Inflammation in ESRD |
|
|
| Completed | 2 | 12 | US | paricalcitol, zemplar, cinacalcet, sensipar | Vanderbilt University | End Stage Renal Disease | 01/10 | 01/10 | | |
NCT00990704: Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism |
|
|
| Completed | 2 | 47 | Japan | paricalcitol, ABT-358, Zemplar, maxacalcitol | Abbott | Secondary Hyperparathyroidism, Hemodialysis | 05/10 | 05/10 | | |
| Completed | 2 | 22 | US | Paricalcitol, Zemplar, Placebo | University of Washington, Abbott | Chronic Kidney Disease | 11/11 | 11/11 | | |
|
| Completed | 2 | 30 | Europe | Zemplar, Placebo | Erling Bjerregaard Pedersen | Chronic Kidney Disease | 12/11 | 12/11 | | |
|
NCT00634582: Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases |
|
|
| Terminated | 2 | 2 | US | paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Metastatic Cancer, Prostate Cancer | 01/13 | 06/15 | | |
| Completed | 2 | 112 | Europe | Paricalcitol, placebo | Mario Negri Institute for Pharmacological Research, Abbott | Type 2 Diabetes | 07/15 | 07/15 | | |
2015-003202-16: DBPC-Dose-finding-trial of Vitamin D3 for SCIT in birch pollen allergic patients |
|
|
| Ongoing | 2 | 48 | Europe | Solution for injection, Zemplar | Academic Medical Centre, AMC | subcutaneous immunotherapy in allergic rhinits (AR) patients with allergies to birchpollen, Allergic rhinitis patients with allergies to birchpollen, Body processes [G] - Immune system processes [G12] | | | | |
2007-006274-29: Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation |
|
|
| Ongoing | 2 | 76 | Europe | Zemplar, Zemplar, Zemplar | Karolinska Institutet at Danderyd University Hospital | Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26)Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26) | | | | |
NCT02686827: DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. |
|
|
| Completed | 2 | 44 | Europe | Paricalcitol, Vitamin D3, (Zemplar), Placebo (for paricalcitol), fluid to mimic paricalcitol injection | Laurian Jongejan | Hypersensitivity | 04/16 | 10/16 | | |
2018-001339-33: A study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with birch pollen allergy |
|
|
| Ongoing | 2 | 40 | Europe | Solution for injection, Zemplar | Academisch medisch centrum Amsterdam, Academisch medisch centrum Amsterdam | subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen, allergic rhinitis patients with allergies to birchpollen, Body processes [G] - Immune system processes [G12] | | | | |
2017-004467-13: Chemotherapy plus paricalcitol in patients with untreated, metastatic pancreatic cancer. |
|
|
| Not yet recruiting | 2 | 14 | Europe | Abraxane, Cisplatin, Gemcitabine, Zemplar, 51642169, Powder for infusion, Concentrate for solution for infusion, Capsule, soft, Abraxane, Cisplatin, Gemcitabine, Zemplar | Barts Health NHS Trust | Stage IV pancreatic adenocarcinoma, Metastatic pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
NCT03331562: A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer |
|
|
| Completed | 2 | 24 | US | Pembrolizumab, Keytruda, paricalcitol, Zemplar, placebo, placebo for paricalcitol | Translational Genomics Research Institute, Stand Up To Cancer, Merck Sharp & Dohme LLC | Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | 06/20 | 07/20 | | |
PINBALL, NCT04054362: Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Unknown status | 2 | 14 | Europe | Paclitaxel protein bound, Cisplatin, Gemcitabine, Paricalcitol | Barts & The London NHS Trust | Pancreatic Cancer | 06/21 | 06/21 | | |
2020-000073-24: A Phase II clinical research study evaluating the effectiveness of paricalcitol in combination with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer. |
|
|
| Not yet recruiting | 2 | 43 | Europe | Paricalcitol, Gemcitabine, Nab-paclitaxel, Capsule, soft, Concentrate for solution for infusion, Powder for solution for infusion, Zemplar®, Gemcitabine, Abraxane | Cancer Trials Ireland, Gateway for Cancer Research | Advanced pancreatic cancer., Advanced pancreatic cancer., Diseases [C] - Cancer [C04] | | | | |
NCT02754726: Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 10 | US | Nivolumab, Opdivo, Albumin-bound paclitaxel, Abraxane, Paricalcitol, Zemplar, Cisplatin, Platinol, Gemcitabine, Gemzar | HonorHealth Research Institute, Translational Genomics Research Institute, Bristol-Myers Squibb, Lustgarten Foundation | Untreated Metastatic Pancreatic Ductal Adenocarcinoma | 04/23 | 12/23 | | |
NCT04524702: Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 12 | US | Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Hydroxychloroquine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Paricalcitol, Compound 49510, Zemplar | Emory University, National Cancer Institute (NCI) | Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | 08/24 | 08/24 | | |
NCT03138720: Pre-operative Treatment for Patients With Untreated Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | Paclitaxel Protein Bound (Abraxane), Cisplatin (Platinal, Gemcitabine (Gemzar), Paricalcitol (Zemplar) | HonorHealth Research Institute | Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer | 03/24 | 12/24 | | |
NABPLAGEMD, NCT03415854: Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma |
|
|
| Completed | 2 | 11 | US | Paricalcitol (Zemplar), Cisplatin (Platinol), Paclitaxel Protein Bound (Abraxane), Gemcitabine (Gemzar) | HonorHealth Research Institute, Barts Cancer Institute, Abramson Cancer Center at Penn Medicine, Salk Institute for Biological Studies, Mayo Clinic, Princeton University, Imaging Endpoints, Translational Genomics Research Institute, Stand Up To Cancer, Cancer Research UK, Lustgarten Foundation, University of California, San Diego | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma | 12/23 | 12/23 | | |
ChiCTR2000034398: Gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody for locally advanced pancreatic cancer: a phase II, single center, single arm study |
|
|
| Not yet recruiting | 2 | 21 | | gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody | Sun Yat-Sen Cancer Center; Sun Yat-Sen Cancer Center, Sponsored by the company | Pancreatic cancer | | | | |
NCT04617067: Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 15 | Europe | Paricalcitol, Gemcitabine (GEM) and Nab-paclitaxel | Cancer Trials Ireland | Advanced Pancreatic Cancer | 09/22 | 09/22 | | |
2016-004827-22: Study to determine the safety/tolerability of the simultaneous treatment of BM41-vaccine and vitamin D 3 in patients with birch pollen allergy. |
|
|
| Terminated | 1/2 | 160 | Europe | BM41 160µg/ml, Suspension for injection, Solution for injection, Zemplar | Academic Medical Center, AMC | moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma), moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without mild to moderate persistent asthma), Body processes [G] - Immune system processes [G12] | | | | |
NCT03520790: Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | US | Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Paricalcitol, Placebo | Dana-Farber Cancer Institute, Stand Up To Cancer, Lustgarten Foundation, American Association for Cancer Research | Pancreatic Cancer | 09/23 | 07/24 | | |
